News for Sanofi Stock (SNY)

Drugs group Sanofi makes Olympic jump in rebrand bid

Reuters • 01/10/24

Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript

Seeking Alpha • 01/09/24

Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

GlobeNewsWire • 01/09/24

7 Rock-Solid Healthcare Dividend Stocks to Buy in January

24/7 Wall Street • 01/06/24

Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target

Business Wire • 01/03/24

AstraZeneca, Sanofi's RSV infant shots approved in China

Reuters • 01/02/24

Here's Why Sanofi (SNY) is a Strong Value Stock

Zacks Investment Research • 01/01/24

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

Zacks Investment Research • 12/22/23

Sanofi suffers major blow as its cutting-edge cancer drug disappoints in Phase III trials

Market Watch • 12/21/23

Sanofi to end cancer research programme evaluating tusamitamab ravtansine

Reuters • 12/21/23

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

GlobeNewsWire • 12/21/23

Sanofi: Expect A Weak 2024 Leading Up To A Strong 2025

Seeking Alpha • 12/20/23

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

Business Wire • 12/19/23

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar

InvestorPlace • 12/17/23

Sanofi gets positive EMA opinion for sleeping sickness treatment

Reuters • 12/15/23

Press Release: Availability of the Q4 2023 Memorandum for modelling purposes

GlobeNewsWire • 12/15/23

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

GlobeNewsWire • 12/15/23

AstraZeneca, Sanofi to supply 230,000 more RSV infant shots to US market

Reuters • 12/14/23

Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects

Zacks Investment Research • 12/12/23

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease

Business Wire • 12/11/23

Sanofi ends licensing deal with Maze Therapeutics after FTC action

Market Watch • 12/11/23

Sanofi terminates deal on drug license after US FTC objects

Reuters • 12/11/23

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

GlobeNewsWire • 12/11/23

6 Health Care Dividend Stocks To By Hand Over Fist

24/7 Wall Street • 12/11/23

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

GlobeNewsWire • 12/11/23